CTRI/2021/05/033695尚未招募3 期
ROLE OF KANAKASAV IN THE MANAGEMENT OF COVID-19 PATIENT WITH SPECIAL REFERENCE TO ARTERIAL BLOOD OXYGEN LEVEL (SpO2)-PROSPECTIVE OPEN LABELLED MULTICENTRIC CLINICAL STUDY
DrPrasad Kulkarni0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Subjects with positive rapid antigen test OR RT-PCR â?? reverse transcription polymerase chain reaction with blood oxygen saturation (SpO2) >= 85 up to 94HRCT score >=7 or above
- •Subjects having at least any one of the diagnostic criteria.
- •Patient between age group 20-70 years of age.
- •Patients of any gender, and willing for trial.
- •Irrespective of socioeconomic condition of patient.
排除标准
- •1) Subjects having critical illness.
- •2) subjects having SPo2 below 85.
- •3) Subjects not willing for trial.
- •4) Pregnant females and lactating mothers.
研究者
相似试验
Unknown
2 期
Assessment of Efficacy of KAN-JANG® in Mild COVID-19Covid19NCT04847518Swedish Herbal Institute AB140
Unknown
1 期
Cannabidiol Treatment for Severe and Critical Coronavirus (COVID-19) Pulmonary InfectionCOVID-19NCT04731116Rabin Medical Center40
Unknown
不适用
Liver Transplantation and Coronavirus Disease 2019 (COVID-19)Covid19Liver TransplantNCT04695756Hospital Italiano de Buenos Aires1,000
已完成
不适用
Efficacy and Safety of Antimicrobial Stewardship Intervention in Hospitalized COVID-19 Patients (COVASP)Covid19COVID-19 PneumoniaCOVID-19 Lower Respiratory InfectionCOVID-19 Acute Respiratory Distress SyndromeSARS-CoV2 InfectionSARS-CoV-2 Acute Respiratory DiseaseNCT04896866University of Alberta833
已完成
2 期
Favipiravir +/- Nitazoxanide: Early Antivirals Combination Therapy in COVID-19Covid19NCT04918927Coordinación de Investigación en Salud, Mexico120